Published in Vaccine Weekly, June 22nd, 2005
"Oral or intranasal administration of mice with rotavirus VP6/LT(R192G) vaccine induces between 95 and 99% protection against fecal shedding of rotavirus after challenge. However, mucosal administration of LT(R192G) is controversial. Subcutaneous, intradermal or Biojector injection induced high titers of serum VP6-specific IgG, eliciting only partial to no protection (73, 0, and 26%, respectively), while transcutaneous delivery using gauze...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly